Alison Abraham
Concepts (303)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 51 | 2024 | 3215 | 3.780 |
Why?
| | Cognitive Dysfunction | 6 | 2023 | 481 | 2.180 |
Why?
| | Retinal Vessels | 4 | 2022 | 79 | 2.000 |
Why?
| | Sexual and Gender Minorities | 6 | 2021 | 269 | 1.960 |
Why?
| | Renal Insufficiency, Chronic | 14 | 2024 | 640 | 1.520 |
Why?
| | Dry Eye Syndromes | 5 | 2024 | 56 | 1.430 |
Why?
| | Glomerular Filtration Rate | 19 | 2024 | 745 | 1.300 |
Why?
| | Homosexuality, Male | 8 | 2021 | 231 | 1.220 |
Why?
| | Tomography, Optical Coherence | 3 | 2023 | 283 | 1.220 |
Why?
| | Viral Load | 10 | 2021 | 526 | 1.130 |
Why?
| | Antiretroviral Therapy, Highly Active | 9 | 2018 | 278 | 1.090 |
Why?
| | Cognition Disorders | 2 | 2023 | 559 | 1.080 |
Why?
| | Vision Disorders | 4 | 2023 | 179 | 1.040 |
Why?
| | Hearing Loss | 4 | 2023 | 177 | 1.020 |
Why?
| | Depression | 4 | 2020 | 1575 | 0.890 |
Why?
| | Bias | 4 | 2022 | 197 | 0.880 |
Why?
| | Vitamin D Deficiency | 2 | 2017 | 189 | 0.860 |
Why?
| | Anti-Retroviral Agents | 5 | 2018 | 250 | 0.840 |
Why?
| | AIDS-Associated Nephropathy | 4 | 2017 | 7 | 0.830 |
Why?
| | Atherosclerosis | 4 | 2022 | 410 | 0.830 |
Why?
| | Hypertension | 6 | 2023 | 1272 | 0.760 |
Why?
| | Anti-HIV Agents | 7 | 2018 | 914 | 0.750 |
Why?
| | Masks | 1 | 2023 | 70 | 0.750 |
Why?
| | Cognitive Aging | 1 | 2023 | 19 | 0.740 |
Why?
| | CD4 Lymphocyte Count | 11 | 2021 | 280 | 0.710 |
Why?
| | Cohort Studies | 26 | 2023 | 6077 | 0.700 |
Why?
| | Fluorescein Angiography | 2 | 2022 | 197 | 0.700 |
Why?
| | Eye | 1 | 2023 | 112 | 0.700 |
Why?
| | Diabetes Mellitus | 5 | 2022 | 1101 | 0.700 |
Why?
| | Male | 59 | 2023 | 73396 | 0.620 |
Why?
| | Cross-Sectional Studies | 19 | 2023 | 5899 | 0.620 |
Why?
| | Adult Survivors of Child Adverse Events | 1 | 2020 | 13 | 0.620 |
Why?
| | Glaucoma | 1 | 2023 | 267 | 0.580 |
Why?
| | Aged | 26 | 2023 | 26432 | 0.570 |
Why?
| | Humans | 87 | 2024 | 146342 | 0.570 |
Why?
| | Viremia | 2 | 2018 | 158 | 0.540 |
Why?
| | Cognition | 4 | 2023 | 1292 | 0.540 |
Why?
| | Middle Aged | 46 | 2021 | 36619 | 0.530 |
Why?
| | Body Size | 1 | 2018 | 91 | 0.530 |
Why?
| | Crime Victims | 1 | 2020 | 131 | 0.530 |
Why?
| | Vitamin D | 2 | 2018 | 402 | 0.520 |
Why?
| | HIV | 6 | 2020 | 249 | 0.520 |
Why?
| | Kidney Diseases | 4 | 2014 | 428 | 0.490 |
Why?
| | Kidney | 12 | 2024 | 1498 | 0.480 |
Why?
| | Survivors | 1 | 2020 | 526 | 0.480 |
Why?
| | Hepatitis C | 4 | 2023 | 251 | 0.470 |
Why?
| | Immunologic Factors | 1 | 2018 | 244 | 0.460 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2018 | 522 | 0.460 |
Why?
| | Microbiota | 1 | 2023 | 725 | 0.440 |
Why?
| | Kidney Failure, Chronic | 3 | 2017 | 589 | 0.430 |
Why?
| | Body Composition | 2 | 2018 | 689 | 0.430 |
Why?
| | Depressive Disorder | 1 | 2018 | 361 | 0.430 |
Why?
| | Risk Factors | 25 | 2024 | 10921 | 0.430 |
Why?
| | Prospective Studies | 19 | 2022 | 8123 | 0.410 |
Why?
| | Dementia | 1 | 2019 | 324 | 0.410 |
Why?
| | Aging | 3 | 2023 | 1996 | 0.400 |
Why?
| | Executive Function | 2 | 2023 | 463 | 0.390 |
Why?
| | Female | 48 | 2024 | 79499 | 0.390 |
Why?
| | Attention | 1 | 2017 | 463 | 0.390 |
Why?
| | Biomarkers | 14 | 2024 | 4340 | 0.370 |
Why?
| | Adult | 44 | 2023 | 41087 | 0.340 |
Why?
| | Substance-Related Disorders | 1 | 2021 | 1100 | 0.340 |
Why?
| | Stress, Psychological | 1 | 2020 | 1171 | 0.340 |
Why?
| | Prevalence | 7 | 2022 | 2861 | 0.330 |
Why?
| | Anemia | 1 | 2012 | 190 | 0.320 |
Why?
| | Comorbidity | 4 | 2021 | 1665 | 0.300 |
Why?
| | Longitudinal Studies | 6 | 2022 | 3017 | 0.290 |
Why?
| | Independent Living | 2 | 2022 | 114 | 0.290 |
Why?
| | Creatinine | 9 | 2023 | 511 | 0.290 |
Why?
| | United States | 18 | 2024 | 16136 | 0.290 |
Why?
| | Hospitals | 2 | 2023 | 738 | 0.280 |
Why?
| | Metabolomics | 3 | 2023 | 738 | 0.270 |
Why?
| | Bone Density | 2 | 2022 | 494 | 0.270 |
Why?
| | Neuropsychological Tests | 4 | 2022 | 1149 | 0.270 |
Why?
| | Aged, 80 and over | 8 | 2023 | 8391 | 0.260 |
Why?
| | Incidence | 9 | 2022 | 2936 | 0.230 |
Why?
| | Sensitivity and Specificity | 3 | 2018 | 1998 | 0.220 |
Why?
| | Iohexol | 2 | 2015 | 23 | 0.210 |
Why?
| | HIV-1 | 5 | 2017 | 913 | 0.210 |
Why?
| | Renal Insufficiency | 2 | 2017 | 173 | 0.210 |
Why?
| | Kidney Function Tests | 4 | 2017 | 156 | 0.210 |
Why?
| | Tears | 1 | 2023 | 29 | 0.200 |
Why?
| | Genes, rRNA | 1 | 2023 | 38 | 0.190 |
Why?
| | Plaque, Atherosclerotic | 1 | 2023 | 60 | 0.190 |
Why?
| | Ophthalmic Solutions | 1 | 2023 | 82 | 0.180 |
Why?
| | Dietary Proteins | 1 | 2023 | 135 | 0.180 |
Why?
| | Optic Disk | 1 | 2023 | 57 | 0.180 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2022 | 51 | 0.180 |
Why?
| | Cornea | 1 | 2023 | 156 | 0.180 |
Why?
| | RNA, Viral | 4 | 2020 | 693 | 0.180 |
Why?
| | Drug Users | 1 | 2022 | 43 | 0.170 |
Why?
| | Cancellous Bone | 1 | 2021 | 22 | 0.170 |
Why?
| | Metabolome | 2 | 2023 | 390 | 0.170 |
Why?
| | Hypotension | 1 | 2023 | 125 | 0.170 |
Why?
| | Epidemiologic Studies | 1 | 2022 | 70 | 0.170 |
Why?
| | Pseudouridine | 1 | 2021 | 4 | 0.170 |
Why?
| | Uridine | 1 | 2021 | 30 | 0.170 |
Why?
| | DNA, Bacterial | 1 | 2023 | 319 | 0.170 |
Why?
| | Femur Neck | 1 | 2021 | 64 | 0.170 |
Why?
| | Alpha-Globulins | 3 | 2017 | 20 | 0.170 |
Why?
| | Odds Ratio | 4 | 2018 | 1077 | 0.160 |
Why?
| | Alcohol Drinking | 2 | 2019 | 850 | 0.160 |
Why?
| | Ascaris | 1 | 2020 | 2 | 0.160 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2023 | 507 | 0.160 |
Why?
| | North America | 3 | 2017 | 300 | 0.160 |
Why?
| | Age Factors | 5 | 2020 | 3347 | 0.160 |
Why?
| | Sickness Impact Profile | 1 | 2020 | 67 | 0.160 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2021 | 2623 | 0.150 |
Why?
| | Survival Analysis | 3 | 2018 | 1378 | 0.150 |
Why?
| | Sex Factors | 4 | 2018 | 2107 | 0.150 |
Why?
| | Adenosine | 1 | 2021 | 256 | 0.150 |
Why?
| | Social Determinants of Health | 1 | 2024 | 317 | 0.150 |
Why?
| | Serum Albumin | 2 | 2024 | 147 | 0.150 |
Why?
| | Malnutrition | 1 | 2020 | 87 | 0.150 |
Why?
| | Kidney Transplantation | 2 | 2017 | 735 | 0.150 |
Why?
| | Visual Acuity | 1 | 2022 | 499 | 0.150 |
Why?
| | Disease Progression | 7 | 2023 | 2867 | 0.140 |
Why?
| | Interleukin-18 | 5 | 2024 | 234 | 0.140 |
Why?
| | Inpatients | 1 | 2023 | 540 | 0.140 |
Why?
| | Retinal Diseases | 1 | 2020 | 102 | 0.140 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2019 | 75 | 0.140 |
Why?
| | Multicenter Studies as Topic | 1 | 2020 | 417 | 0.140 |
Why?
| | Follow-Up Studies | 5 | 2021 | 5439 | 0.140 |
Why?
| | Glucocorticoids | 1 | 2022 | 536 | 0.140 |
Why?
| | Epidemiologic Research Design | 1 | 2018 | 27 | 0.130 |
Why?
| | Prediabetic State | 1 | 2021 | 250 | 0.130 |
Why?
| | Prognosis | 5 | 2018 | 4351 | 0.130 |
Why?
| | Cerebrovascular Disorders | 1 | 2019 | 103 | 0.130 |
Why?
| | Bisexuality | 1 | 2018 | 39 | 0.130 |
Why?
| | Hand Strength | 2 | 2022 | 149 | 0.130 |
Why?
| | Substance Abuse, Intravenous | 2 | 2017 | 131 | 0.130 |
Why?
| | AIDS-Related Opportunistic Infections | 2 | 2016 | 130 | 0.130 |
Why?
| | Hyperglycemia | 1 | 2021 | 384 | 0.130 |
Why?
| | Hypercholesterolemia | 1 | 2018 | 95 | 0.130 |
Why?
| | Cystatin C | 2 | 2016 | 65 | 0.130 |
Why?
| | Acetylglucosaminidase | 2 | 2016 | 8 | 0.130 |
Why?
| | Case-Control Studies | 6 | 2023 | 3647 | 0.130 |
Why?
| | Dihydroxycholecalciferols | 1 | 2016 | 1 | 0.120 |
Why?
| | Coronary Artery Disease | 1 | 2023 | 751 | 0.120 |
Why?
| | HIV Seropositivity | 2 | 2017 | 118 | 0.120 |
Why?
| | Sustained Virologic Response | 1 | 2017 | 48 | 0.120 |
Why?
| | Tenofovir | 2 | 2016 | 300 | 0.120 |
Why?
| | Albuminuria | 4 | 2023 | 190 | 0.120 |
Why?
| | Acute-Phase Proteins | 2 | 2013 | 66 | 0.120 |
Why?
| | Geriatric Assessment | 1 | 2018 | 244 | 0.120 |
Why?
| | Lipocalins | 2 | 2013 | 35 | 0.120 |
Why?
| | HIV Wasting Syndrome | 1 | 2016 | 3 | 0.120 |
Why?
| | Retrospective Studies | 6 | 2023 | 17438 | 0.120 |
Why?
| | Data Interpretation, Statistical | 1 | 2018 | 368 | 0.120 |
Why?
| | Time Factors | 5 | 2018 | 7109 | 0.120 |
Why?
| | Machine Learning | 1 | 2022 | 594 | 0.110 |
Why?
| | Living Donors | 1 | 2017 | 216 | 0.110 |
Why?
| | Geography | 1 | 2016 | 187 | 0.110 |
Why?
| | Hemoglobins | 2 | 2020 | 384 | 0.110 |
Why?
| | Continuity of Patient Care | 1 | 2017 | 298 | 0.110 |
Why?
| | Apolipoproteins | 1 | 2014 | 38 | 0.110 |
Why?
| | Inflammation | 3 | 2018 | 2919 | 0.110 |
Why?
| | Young Adult | 9 | 2023 | 14330 | 0.110 |
Why?
| | Patient Care | 1 | 2016 | 120 | 0.110 |
Why?
| | Alzheimer Disease | 1 | 2021 | 641 | 0.110 |
Why?
| | Adolescent | 10 | 2023 | 22557 | 0.100 |
Why?
| | Arsenic | 1 | 2015 | 66 | 0.100 |
Why?
| | Immune Tolerance | 1 | 2017 | 386 | 0.100 |
Why?
| | Sleep Wake Disorders | 1 | 2018 | 314 | 0.100 |
Why?
| | Reproducibility of Results | 2 | 2023 | 3416 | 0.100 |
Why?
| | Lipoproteins, HDL | 1 | 2014 | 104 | 0.100 |
Why?
| | Canada | 4 | 2017 | 432 | 0.100 |
Why?
| | Factor Analysis, Statistical | 1 | 2015 | 298 | 0.100 |
Why?
| | Models, Theoretical | 1 | 2017 | 561 | 0.100 |
Why?
| | HIV Seronegativity | 1 | 2013 | 28 | 0.100 |
Why?
| | Kidney Tubules, Proximal | 1 | 2014 | 127 | 0.100 |
Why?
| | Graft Rejection | 1 | 2017 | 516 | 0.100 |
Why?
| | Lipodystrophy | 1 | 2013 | 12 | 0.100 |
Why?
| | Kidney Glomerulus | 1 | 2014 | 129 | 0.100 |
Why?
| | beta 2-Microglobulin | 1 | 2013 | 47 | 0.100 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2013 | 89 | 0.090 |
Why?
| | Proto-Oncogene Proteins | 2 | 2013 | 616 | 0.090 |
Why?
| | Organophosphonates | 1 | 2013 | 95 | 0.090 |
Why?
| | Antibodies, Fungal | 1 | 2011 | 8 | 0.090 |
Why?
| | Pneumocystis carinii | 1 | 2011 | 12 | 0.080 |
Why?
| | Patient Compliance | 1 | 2015 | 589 | 0.080 |
Why?
| | Pneumonia, Pneumocystis | 1 | 2011 | 34 | 0.080 |
Why?
| | Renal Dialysis | 1 | 2015 | 461 | 0.080 |
Why?
| | Motor Activity | 1 | 2016 | 704 | 0.080 |
Why?
| | Cardiovascular Diseases | 1 | 2023 | 2219 | 0.080 |
Why?
| | Dyslipidemias | 1 | 2013 | 184 | 0.080 |
Why?
| | Baltimore | 2 | 2021 | 71 | 0.080 |
Why?
| | Fungal Proteins | 1 | 2011 | 137 | 0.080 |
Why?
| | Medication Adherence | 1 | 2015 | 535 | 0.080 |
Why?
| | Adenine | 1 | 2013 | 339 | 0.080 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 3 | 2016 | 42 | 0.080 |
Why?
| | Risk Assessment | 3 | 2018 | 3712 | 0.080 |
Why?
| | Patient Acceptance of Health Care | 1 | 2017 | 881 | 0.080 |
Why?
| | Healthcare Disparities | 1 | 2017 | 733 | 0.080 |
Why?
| | Lipocalin-2 | 3 | 2016 | 80 | 0.070 |
Why?
| | Predictive Value of Tests | 4 | 2016 | 2113 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2015 | 2921 | 0.070 |
Why?
| | Acute Kidney Injury | 1 | 2016 | 866 | 0.070 |
Why?
| | Child | 7 | 2023 | 22693 | 0.070 |
Why?
| | Homicide | 1 | 2008 | 65 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 6073 | 0.060 |
Why?
| | Proportional Hazards Models | 3 | 2017 | 1331 | 0.060 |
Why?
| | Health Services Accessibility | 1 | 2015 | 1107 | 0.060 |
Why?
| | Hepacivirus | 2 | 2022 | 237 | 0.060 |
Why?
| | Brain | 1 | 2019 | 2991 | 0.060 |
Why?
| | Membrane Glycoproteins | 3 | 2013 | 495 | 0.060 |
Why?
| | Child, Preschool | 4 | 2023 | 11913 | 0.050 |
Why?
| | Primary Health Care | 1 | 2015 | 1776 | 0.050 |
Why?
| | Stroke | 1 | 2013 | 1287 | 0.050 |
Why?
| | Diet, Protein-Restricted | 1 | 2023 | 11 | 0.050 |
Why?
| | Population Surveillance | 2 | 2017 | 481 | 0.050 |
Why?
| | Intelligence | 1 | 2023 | 119 | 0.050 |
Why?
| | Loteprednol Etabonate | 1 | 2022 | 5 | 0.050 |
Why?
| | Lubricant Eye Drops | 1 | 2022 | 9 | 0.050 |
Why?
| | Chi-Square Distribution | 2 | 2014 | 517 | 0.050 |
Why?
| | Treatment Outcome | 1 | 2018 | 11821 | 0.050 |
Why?
| | Receptors, Virus | 2 | 2013 | 91 | 0.050 |
Why?
| | Meibomian Glands | 1 | 2022 | 18 | 0.050 |
Why?
| | Research Design | 2 | 2021 | 1143 | 0.050 |
Why?
| | Constriction, Pathologic | 1 | 2023 | 240 | 0.050 |
Why?
| | Tobramycin | 1 | 2022 | 63 | 0.050 |
Why?
| | Support Vector Machine | 1 | 2022 | 33 | 0.040 |
Why?
| | Sugar Acids | 1 | 2021 | 4 | 0.040 |
Why?
| | Retinal Ganglion Cells | 1 | 2023 | 124 | 0.040 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2022 | 43 | 0.040 |
Why?
| | Citrates | 1 | 2021 | 41 | 0.040 |
Why?
| | Cyclosporine | 1 | 2022 | 256 | 0.040 |
Why?
| | Linear Models | 2 | 2014 | 857 | 0.040 |
Why?
| | Hearing | 1 | 2022 | 102 | 0.040 |
Why?
| | Neoplasms | 1 | 2017 | 2954 | 0.040 |
Why?
| | Memory, Short-Term | 1 | 2023 | 276 | 0.040 |
Why?
| | Eating | 1 | 2023 | 386 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2022 | 175 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2021 | 173 | 0.040 |
Why?
| | Infant | 3 | 2023 | 10114 | 0.040 |
Why?
| | Renal Replacement Therapy | 1 | 2021 | 102 | 0.040 |
Why?
| | Sulfides | 1 | 2021 | 92 | 0.040 |
Why?
| | Los Angeles | 1 | 2020 | 73 | 0.040 |
Why?
| | Alanine | 1 | 2021 | 171 | 0.040 |
Why?
| | Audiometry, Pure-Tone | 1 | 2020 | 25 | 0.040 |
Why?
| | Tryptophan | 1 | 2021 | 184 | 0.040 |
Why?
| | Cataract | 1 | 2022 | 240 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2022 | 486 | 0.040 |
Why?
| | Microcirculation | 1 | 2020 | 142 | 0.040 |
Why?
| | Hydrocortisone | 1 | 2021 | 303 | 0.040 |
Why?
| | Frailty | 1 | 2022 | 208 | 0.040 |
Why?
| | Genotype | 2 | 2014 | 1879 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2020 | 426 | 0.030 |
Why?
| | Heterosexuality | 1 | 2018 | 49 | 0.030 |
Why?
| | Blood Glucose | 2 | 2021 | 2360 | 0.030 |
Why?
| | Multimorbidity | 1 | 2018 | 65 | 0.030 |
Why?
| | Diabetic Retinopathy | 1 | 2020 | 211 | 0.030 |
Why?
| | Glucose | 1 | 2022 | 1053 | 0.030 |
Why?
| | Logistic Models | 1 | 2022 | 2126 | 0.030 |
Why?
| | Blood Pressure | 1 | 2023 | 1765 | 0.030 |
Why?
| | History, 21st Century | 1 | 2017 | 224 | 0.030 |
Why?
| | Patient Outcome Assessment | 1 | 2017 | 129 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 1763 | 0.030 |
Why?
| | Nephrectomy | 1 | 2017 | 172 | 0.030 |
Why?
| | Diet | 1 | 2023 | 1273 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2020 | 1327 | 0.030 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2016 | 80 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2016 | 329 | 0.030 |
Why?
| | Demography | 1 | 2016 | 274 | 0.030 |
Why?
| | Apolipoprotein L1 | 1 | 2014 | 14 | 0.030 |
Why?
| | Ultrasonography | 1 | 2019 | 788 | 0.030 |
Why?
| | Graft Survival | 1 | 2017 | 523 | 0.030 |
Why?
| | Risk | 1 | 2017 | 920 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1707 | 0.030 |
Why?
| | Proteinuria | 1 | 2014 | 103 | 0.020 |
Why?
| | Health | 1 | 2014 | 81 | 0.020 |
Why?
| | Nutrition Surveys | 1 | 2015 | 270 | 0.020 |
Why?
| | Diagnostic Errors | 1 | 2014 | 178 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2016 | 471 | 0.020 |
Why?
| | Health Policy | 1 | 2016 | 399 | 0.020 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2013 | 162 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2018 | 801 | 0.020 |
Why?
| | Databases, Factual | 1 | 2018 | 1493 | 0.020 |
Why?
| | Cholesterol, HDL | 1 | 2013 | 201 | 0.020 |
Why?
| | Absorptiometry, Photon | 1 | 2013 | 278 | 0.020 |
Why?
| | Alleles | 1 | 2014 | 907 | 0.020 |
Why?
| | Cholesterol, LDL | 1 | 2013 | 363 | 0.020 |
Why?
| | Cholesterol | 1 | 2013 | 411 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2014 | 1543 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2014 | 399 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2013 | 429 | 0.020 |
Why?
| | Triglycerides | 1 | 2013 | 527 | 0.020 |
Why?
| | Serine Endopeptidases | 1 | 2011 | 129 | 0.020 |
Why?
| | Immunoglobulin M | 1 | 2011 | 284 | 0.020 |
Why?
| | Animals | 2 | 2023 | 38107 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 846 | 0.020 |
Why?
| | Social Problems | 1 | 2008 | 12 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2013 | 784 | 0.020 |
Why?
| | Tanzania | 1 | 2008 | 76 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2013 | 642 | 0.020 |
Why?
| | Age Distribution | 1 | 2008 | 399 | 0.020 |
Why?
| | Sex Distribution | 1 | 2008 | 382 | 0.020 |
Why?
| | Chronic Disease | 1 | 2013 | 1827 | 0.020 |
Why?
| | Immunoglobulin G | 1 | 2011 | 901 | 0.020 |
Why?
| | Cause of Death | 1 | 2008 | 456 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2014 | 2488 | 0.010 |
Why?
| | Insulin Resistance | 1 | 2013 | 1247 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2013 | 2786 | 0.010 |
Why?
|
|
Abraham's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|